Biotest
Oliver Hein currently serves as the Chief Corporate Risk & Compliance Officer at Biotest AG, a position held since January 2017. Prior to this role, Oliver worked at Ernst & Young Law as a lawyer focusing on legal compliance from April 2013 to December 2016. Additional experience includes a position as a lawyer at KPMG Rechtsanwaltsgesellschaft mbH, specializing in compliance and corporate law from May 2007 to March 2013, and at Ashurst, where responsibilities included M&A, corporate law, finance, and criminal compliance from October 2001 to April 2007. Oliver began a legal career at Gleiss Lutz, practicing corporate and commercial law from November 2000 to September 2001. Academically, Oliver obtained a Staatsexamen in legal compliance and corporate law from Goethe University Frankfurt (1990-1993) and a Licentiate degree in Droit from Université Toulouse - Jean Jaurès (1989-1990).
This person is not in any offices
Biotest
Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology and intensive care medicine. Biotest AG develops, manufactures and markets immunoglobulin, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.